Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Neurol.

Sec. Stroke

Volume 16 - 2025 | doi: 10.3389/fneur.2025.1611794

This article is part of the Research TopicQuality of Stroke Care: What Could Be Improved, and How? - Volume IIView all 20 articles

Therapeutic Hypothermia with Rapid Thin Liquid Convection Is Safe and Feasible in Acute Stroke Patients: The SISCO Pilot Study

Provisionally accepted
Justin  A. SalerianJustin A. Salerian1Robert  B. SchockRobert B. Schock2*Clemens  M. SchirmerClemens M. Schirmer3Souvik  SenSouvik Sen4Sheryl  Martin-SchildSheryl Martin-Schild5Oded  GorenOded Goren3Douglas  F, KupasDouglas F, Kupas3Robert  J. FreedmanRobert J. Freedman2Aimee  AysenneAimee Aysenne1
  • 1School of Medicine, Tulane University, New Orleans, Louisiana, United States
  • 2Life Recovery Systems, Kinnelon, United States
  • 3Geisinger Medical Center, Danville, Pennsylvania, United States
  • 4University of South Carolina, Columbia, Missouri, United States
  • 5Dr. Brain, Inc., Metairie, Louisiana, United States

The final, formatted version of the article will be published soon.

Background: Laboratory studies have shown that rapid therapeutic hypothermia (TH) of <34°C can reduce stroke infarct volume by over 50%. The EuroHyp-1 and ICTUS 2/3 trials found no benefits in the slow cooling of ischemic stroke patients, while extensive shivering was observed. More powerful cooling methods are required to improve outcomes. Methods: In a feasibility study approved to include up to 30 patients, the ThermoSuit® System (TSS) was used to cool sedated ischemic stroke patients to 32-34°C. Patients were cooled after reperfusion, and TH was maintained for 24 hours. Cooling speeds, adverse events, and neurological outcomes (including Modified Rankin Score (mRS) at 90 days) were documented. Results: The trial was terminated after enrolling 14 subjects from 3 sites after meeting the study feasibility criteria. Ten subjects qualified for outcomes analysis. All cooled patients reached the 34°C target with a median time of 40 minutes. Patients cooled under this protocol showed no increased harm and trends for improved neurological outcomes compared to previously published studies. A pneumonia rate of 23% (3/13) was comparable to prior studies in which stroke patients were cooled. Brief shivering occurred in most patients but was limited to 5.4% of the time while in the hypothermic temperature range. Patients cooled per the SISCO protocol had a rate of acceptable outcomes (mRS≤3) of 90%. In intention-to-treat analysis, 82% of patients had acceptable outcomes. Discussion: The TSS is a feasible tool to achieve TH in ischemic stroke patients. This non-invasive cooling technique allows swift cooling of patients to ≤ 34°C with little shivering and no apparent safety issues. Further studies are warranted to prove this rapid cooling method is cytoprotective in stroke patients, as evidenced by improved odds of functional independence.

Keywords: Hypothermia, ischemic stroke, Cytoprotection, Pneumonia, Stroke, Therapeutics

Received: 14 Apr 2025; Accepted: 28 Sep 2025.

Copyright: © 2025 Salerian, Schock, Schirmer, Sen, Martin-Schild, Goren, Kupas, Freedman and Aysenne. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Robert B. Schock, bschock@life-recovery.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.